Lymphocytic Leukemia, Chronic Clinical Trial
Official title:
Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status
Verified date | August 2017 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.
Status | Terminated |
Enrollment | 89 |
Est. completion date | May 4, 2016 |
Est. primary completion date | May 4, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of previously untreated B-cell CLL confirmed immunophenotypically - For participants, age 60-70 years: Cumulative Illness Rating Scale (CIRS) comorbidity score less than or equal to (</=) 6 - Binet stage B, C or A with progression - Life expectancy greater than or equal to (>/=) 12 months - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 - Women of child bearing potential and men should agree to use highly reliable contraceptive method throughout the treatment period and within 12 months after treatment completion Exclusion Criteria: - Participants with small-cell lymphoma - Participants with auto-immune hemolytic anemia - Concomitant malignant disease during enrollment, except basal cell carcinoma of the skin - Chemotherapy for concomitant malignant disease given within 12 months prior to study enrollment - Participants with Richter's Syndrome - Participants with symptomatic Hepatitis B infection - Any clinically significant infection that could not be cured prior to enrollment, including Human Immunodeficiency Virus (HIV) infection - Creatinine clearance less than (<) 30 milliliters per minute (mL/min) - Participants with congestive heart failure (CHF) New York Heart Association (NYHA) III-IV - Participants with liver failure and acute hepatitis of any etiology - Any other medical or mental condition which may preclude from receiving the entire course of protocol specified treatment or signing the informed consent - History of an anaphylactic reaction to murine antibodies, proteins, or any other ingredient of rituximab - Pregnancy and breast-feeding women |
Country | Name | City | State |
---|---|---|---|
Russian Federation | The order of Honour pin Irkutsk regional clinical hospital; Hematology Department | Irkutsk | |
Russian Federation | Kemerovo Regional Clinical Hospital | Kemerovo | |
Russian Federation | Regional Clinical Oncology Despensary #1; Hematology Department | Krasnodar | |
Russian Federation | City Clinical Hospital After Botkin; Hematology | Moscow | |
Russian Federation | N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis | Moscow | |
Russian Federation | City Clinical Hospital #15; Hematology department | Saint-Petersburg | |
Russian Federation | Leningrad Regional Clinical Hospital; Hematology #1 | St Petersburg | |
Russian Federation | Saint-Petersburg SHI City Clinical Hospital #31 | St. Petersburg | |
Russian Federation | GUZ Tula Regioanal Clinical Hospital; Hematology | Tula | |
Russian Federation | Republican clinical hospital named after G.G. Kuvatov | UFA |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Complete Remission | Complete remission was defined as the disappearance of all signs of disease. | Up to approximately 5 years | |
Primary | Percentage of Participants With Disease Progression | Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. | Up to approximately 5 years | |
Primary | Percentage of Participants With Stable Disease | Stable disease was defined as not meeting the criteria for partial remission or disease progression | Up to approximately 5 years | |
Primary | Percentage of Participants With Partial Remission | Partial remission was defined as a reduction in tumor size by >50%. | Up to approximately 5 years | |
Primary | Duration of Response | Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by >50%. | Up to approximately 5 years | |
Primary | Progression-free Survival | Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. | Up to approximately 5 years | |
Primary | Event-free Survival | Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by >50%. | Up to approximately 5 years | |
Primary | Overall Survival | Overall survival was defined as the time period from the first day of study treatment to participant death. | Up to approximately 5 years | |
Primary | Percentage of Participants With Phenotypic Remission | Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells =0.01% of the total number of peripheral leukocytes. | Up to approximately 5 years | |
Primary | Percentage of Participants With Adverse Events (AEs) and Serious AEs | An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria. | Up to approximately 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01072240 -
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
|
N/A | |
Completed |
NCT00754650 -
A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02500407 -
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04704323 -
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
|
||
Active, not recruiting |
NCT01414205 -
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)
|
Phase 2 | |
Completed |
NCT01224093 -
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
|
N/A | |
Completed |
NCT01395615 -
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia
|
N/A | |
Completed |
NCT00532129 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT02013817 -
CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
|
Phase 2 | |
Completed |
NCT01685892 -
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT00738374 -
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
|
Phase 2 | |
Completed |
NCT00241358 -
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01056510 -
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
|
Phase 4 | |
Completed |
NCT01300247 -
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
|
Phase 1 | |
Completed |
NCT00718549 -
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
Completed |
NCT01263704 -
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00431873 -
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT01178086 -
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
||
Terminated |
NCT02292225 -
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
|
Phase 1 | |
Completed |
NCT02533401 -
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 |